www.axsome.com Open in urlscan Pro
2600:9000:2248:aa00:19:4619:b8c0:93a1  Public Scan

Form analysis
0 forms found in the DOM

Text Content

Skip to main content
 * About Axsome About Axsome
   * AllAll
   * Overview
   * Management Team
   * Board of Directors
   * Intellectual Property
   * State Disclosures
 * Portfolio Portfolio
   * AllAll
   * Products Overview   Products Overview  
     * AllAll
     * Overview
     * Auvelity™ (dextromethorphan-bupropion)
     * Sunosi® (solriamfetol)
   * Pipeline Overview   Pipeline Overview  
     * AllAll
     * Overview
     * AXS-05
     * AXS-07
     * AXS-12
     * AXS-14
 * Conditions Conditions
   * AllAll
   * Overview
   * Depression
   * Migraine
   * Alzheimer’s
     Disease Agitation
   * Excessive Daytime
     Sleepiness
   * Narcolepsy
   * Fibromyalgia
   * Smoking Cessation
 * 
 * Science Science
   * AllAll
   * Overview
   * Medical Information U.S.
   * Medical Information International
   * Publications
 * Investors Investors
   * AllAll
   * Overview
   * Corporate Governance
   * Stock Information
   * Financial Information
   * News & Events
   * Webcasts &
     Presentations
   * Analyst Coverage
   * Shareholder Services
 * Careers Careers
   * AllAll
   * Overview
   * Current Opportunities

New product approved
for adults with major depressive disorder      view press release


TURNING PATIENT NEEDS INTO BREAKTHROUGH DISCOVERIES.


TURNING PATIENT
NEEDS INTO
BREAKTHROUGH
DISCOVERIES.

about axsome


WE ARE COMMITTED TO DEVELOPING PRODUCTS THAT MEANINGFULLY IMPROVE THE LIVES OF
PATIENTS.

Axsome is developing innovative treatments including AXS-05, AXS-07, AXS-12,
and AXS‑14.

learn about our pipeline

Axsome focuses on CNS conditions including depression, Alzheimer's disease
agitation, migraine, narcolepsy and fibromyalgia.

learn about these CNS conditions & more
AXS-05 AXS-07
AXS-12 AXS-14

--------------------------------------------------------------------------------


RECENT NEWS

Auvelity™ is now approved!

Please see full Prescribing Information, including Boxed Warning, and the
Medication Guide.

view website

Axsome Therapeutics Completes U.S. Acquisition of Sunosi®

Please see full Prescribing Information and Medication Guide.

view press release

September 21, 2022

Axsome Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference

Click here to read more

September 14, 2022

Axsome Therapeutics to Present at the Cowen 2nd Annual Novel Mechanisms in
Neuropsychiatry Summit

Click to here read more

September 8, 2022

Axsome Therapeutics Initiates ADVANCE-2 Phase 3 Trial of AXS-05 in Alzheimer’s
Disease Agitation

Click to here read more
See all News


WORKING AT AXSOME

Join our team! Take a look at available positions.

see opportunities


YOUR PRIVACY IS IMPORTANT TO US

By clicking "accept all cookies", you consent to the storing of cookies on your
device for improving site navigation, analyzing site usage, and assisting in our
marketing efforts.
Privacy Notice

accept all cookies
 * About Axsome About Axsome
   * AllAll
   * Overview
   * Management Team
   * Board of Directors
   * Intellectual Property
   * State Disclosures
 * Portfolio Portfolio
   * AllAll
   * Products Overview   Products Overview  
     * AllAll
     * Overview
     * Auvelity™ (dextromethorphan-bupropion)
     * Sunosi® (solriamfetol)
   * Pipeline Overview   Pipeline Overview  
     * AllAll
     * Overview
     * AXS-05
     * AXS-07
     * AXS-12
     * AXS-14
 * Conditions Conditions
   * AllAll
   * Overview
   * Depression
   * Migraine
   * Alzheimer’s
     Disease Agitation
   * Excessive Daytime
     Sleepiness
   * Narcolepsy
   * Fibromyalgia
   * Smoking Cessation
 * 
 * Science Science
   * AllAll
   * Overview
   * Medical Information U.S.
   * Medical Information International
   * Publications
 * Investors Investors
   * AllAll
   * Overview
   * Corporate Governance
   * Stock Information
   * Financial Information
   * News & Events
   * Webcasts &
     Presentations
   * Analyst Coverage
   * Shareholder Services
 * Careers Careers
   * AllAll
   * Overview
   * Current Opportunities

 * Contact Us
 * Privacy Notice
 * Terms of Use
 * 
 * 

AXSOME and its logos are trademarks or registered trademarks of Axsome
Therapeutics, Inc. or its affiliates. Other trademarks are property of their
respective owners.


© 2022 Axsome Therapeutics, Inc. All rights reserved. 22 Cortlandt St, 16th
Floor, New York, NY 10007 info@axsome.com


YOU ARE ABOUT TO
LEAVE AXSOME.COM

You will now be sent to a website that is not controlled or owned by Axsome
Therapeutics, Inc. Axsome Therapeutics, Inc. is not responsible or liable for
the website you are about to go to, which may not be appropriate for everyone.

continue cancel



THANK YOU FOR REGISTERING.




THERE HAS BEEN AN ERROR ON THE FORM SUBMISSION. PLEASE TRY AGAIN.

close


NOUS VOUS REMERCIONS DE VOTRE INSCRIPTION.


UNE ERREUR S'EST PRODUITE LORS DE LA SOUMISSION DU FORMULAIRE. VEUILLEZ
RÉESSAYER.

close